Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2024-04-25 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于公司2024年第一季度主要经营数据的公告
Interim / Quarterly Report Classification · 95% confidence The document is titled as an announcement regarding the company's main operating data for the first quarter of 2024. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment field, product, and region for the quarter. The document explicitly states it is a disclosure of main operating data for the first quarter and is unaudited. The length is 2846 characters, which is relatively short but contains substantive financial data for a quarterly period. It is not a full interim report but a quarterly operating data announcement. According to the definitions, an Interim/Quarterly Report (IR) must contain actual financial statements or substantive financial data and analysis, which this document does. Therefore, this document fits best as an Interim / Quarterly Report (IR). Q1 2024
2024-04-25 Chinese
天士力2023年年度股东大会会议资料
AGM Information Classification · 100% confidence The document is titled '2023 年年度股东大会会议资料' which translates to '2023 Annual General Meeting (AGM) Meeting Materials'. It includes detailed agenda items for the 2023 AGM, such as reports from the board and supervisory committee, financial reports, profit distribution plans, election of directors and supervisors, and voting procedures. The content is comprehensive and clearly intended for use during the AGM, including voting methods and meeting logistics. The document length is about 15,000 characters, indicating it is a full set of meeting materials rather than a brief announcement or summary. Therefore, this document fits the category of AGM Information (AGM-R).
2024-04-24 Chinese
天士力关于2024年度预计发生的日常关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the year 2024. It includes descriptions of the nature of transactions, pricing policies, counterparties, financial data of related parties, and the impact of these transactions on the company. The document is titled as an announcement and contains no financial statements or comprehensive financial performance data. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory announcement about related party transactions, which is a common disclosure in regulatory filings. The document length is about 11,688 characters, which is substantial but the content is focused on disclosure of related party transactions rather than a full financial report. Therefore, the best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories like Annual Report or Interim Report.
2024-04-15 Chinese
天士力第八届董事会第26次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 26th meeting of the 8th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals related to the 2023 fiscal year, such as the general manager's work report, board work report, audit committee report, financial statements, profit distribution plan, annual report, social responsibility report, internal control reports, and other governance matters. The document also discusses the nomination and election of independent and non-independent directors for the 9th Board, and notices about the upcoming 2023 Annual General Meeting. The document is not the reports themselves but an official announcement of the board meeting resolutions and related voting outcomes. It references that the full reports are published on the Shanghai Stock Exchange website. The document length is 6703 characters, which is relatively short for full reports but appropriate for a meeting resolution announcement. Therefore, this document fits best into the category of Board/Management Information (MANG), as it announces board meeting decisions and management-related information, including director nominations and board resolutions.
2024-04-15 Chinese
天士力第八届监事会第15次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 15th meeting of the 8th Supervisory Board of TianShiLi Pharmaceutical Group Co., Ltd. It includes voting results on various reports and proposals such as the 2023 General Manager Work Report, 2023 Supervisory Board Work Report, 2023 Financial Final Accounts Report, 2023 Profit Distribution Plan, the full 2023 Annual Report and its summary, the 2023 Internal Control Evaluation Report, and proposals related to 2024 expected related party transactions and Supervisory Board re-election. The document also contains detailed candidate resumes for the new Supervisory Board members. The content is focused on board/management decisions, supervisory board meeting resolutions, and governance matters rather than the full annual report itself. The document length is under 5,000 characters and it is an announcement of meeting resolutions and approvals, not the full annual report or financial statements. Therefore, it fits best under Board/Management Information (MANG).
2024-04-15 Chinese
天士力关于公司2023年度主要经营数据的公告
Regulatory Filings Classification · 90% confidence The document is titled as an announcement regarding the company's main operating data for the year 2023. It contains detailed financial data such as revenue, cost, and gross margin segmented by industry, treatment field, product, and region. The document is relatively short (2974 characters) and is presented as a data disclosure announcement rather than a full annual report. There is no indication that this is a full Annual Report (10-K) or Interim Report (IR), nor is it a certification or a regulatory filing of another type. The document is a disclosure of key operating data for the year, which aligns with a Capital/Financing Update (CAP) or possibly a Regulatory Filing (RNS). However, since it is specifically about main operating data for the year and not a full financial report, and it is an official announcement by the board, the best fit is Regulatory Filings (RNS) as a general disclosure of operating data. The document does not fit the criteria for Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and analysis. It is not a report publication announcement (RPA) because it contains substantive data, not just a notice of report availability. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-04-15 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.